CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation.
Gao J, Wang Z, Jiang W, Zhang Y, Meng Z, Niu Y, Sheng Z, Chen C, Liu X, Chen X, Liu C, Jia K, Zhang C, Liao H, Jung J, Sung E, Chung H, Zhang JZ, Zhu AX, Shen L.
Gao J, et al.
J Immunother Cancer. 2023 Jun;11(6):e006704. doi: 10.1136/jitc-2023-006704.
J Immunother Cancer. 2023.
PMID: 37364935
Free PMC article.